SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using a proprietary electroporation-based DNA delivery platform, announced today it has expanded its research license with the International AIDS Vaccine Initiative (IAVI), a leading organization dedicated to ensuring the development of safe and effective preventive HIV vaccines. Inovio’s electroporation delivery technology is intended to enhance the potency of DNA vaccines against cancers and infectious diseases by increasing the cellular uptake of an agent by 1,000 times or more. This technology also has the potential to induce significant antibody and T-cell immune responses, both of which scientists believe will be critical to developing a preventive HIV vaccine.
